NAGIREDDY PUTLURI to Breast Neoplasms
This is a "connection" page, showing publications NAGIREDDY PUTLURI has written about Breast Neoplasms.
Connection Strength
0.928
-
Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance. Neoplasia. 2014 May; 16(5):390-402.
Score: 0.190
-
MYC Induces Oncogenic Stress through RNA Decay and Ribonucleotide Catabolism in Breast Cancer. Cancer Discov. 2024 Sep 04; 14(9):1699-1716.
Score: 0.097
-
Metabolomic Rewiring Promotes Endocrine Therapy Resistance in Breast Cancer. Cancer Res. 2024 01 16; 84(2):291-304.
Score: 0.093
-
UDP-glucose 6-dehydrogenase regulates hyaluronic acid production and promotes breast cancer progression. Oncogene. 2020 04; 39(15):3089-3101.
Score: 0.068
-
Liver- and Microbiome-derived Bile Acids Accumulate in Human Breast Tumors and Inhibit Growth and Improve Patient Survival. Clin Cancer Res. 2019 10 01; 25(19):5972-5983.
Score: 0.068
-
Expression of Long Noncoding RNA YIYA Promotes Glycolysis in Breast Cancer. Cancer Res. 2018 08 15; 78(16):4524-4532.
Score: 0.063
-
Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer. Nature. 2018 04; 556(7700):249-254.
Score: 0.062
-
Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer. J Clin Invest. 2018 04 02; 128(4):1283-1299.
Score: 0.062
-
ADHFE1 is a breast cancer oncogene and induces metabolic reprogramming. J Clin Invest. 2018 01 02; 128(1):323-340.
Score: 0.061
-
EMT-induced metabolite signature identifies poor clinical outcome. Oncotarget. 2015 Dec 15; 6(40):42651-60.
Score: 0.053
-
MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest. 2014 Jan; 124(1):398-412.
Score: 0.046
-
Application of 13C isotope labeling using liquid chromatography mass spectrometry (LC-MS) to determining phosphate-containing metabolic incorporation. J Mass Spectrom. 2013 Dec; 48(12):1270-5.
Score: 0.046
-
Analysis of cerebrospinal fluid metabolites in patients with primary or metastatic central nervous system tumors. Acta Neuropathol Commun. 2018 08 31; 6(1):85.
Score: 0.016